CN103153308B - Trpa1受体拮抗剂 - Google Patents

Trpa1受体拮抗剂 Download PDF

Info

Publication number
CN103153308B
CN103153308B CN201180049452.3A CN201180049452A CN103153308B CN 103153308 B CN103153308 B CN 103153308B CN 201180049452 A CN201180049452 A CN 201180049452A CN 103153308 B CN103153308 B CN 103153308B
Authority
CN
China
Prior art keywords
pain
purposes
compound
antalgesic
various
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180049452.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103153308A (zh
Inventor
M.斯文森
D.威格尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akturam Life Co ltd
Akturam Real Estate Co ltd
Original Assignee
Acturum Life Science AB
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acturum Life Science AB, AstraZeneca AB filed Critical Acturum Life Science AB
Publication of CN103153308A publication Critical patent/CN103153308A/zh
Application granted granted Critical
Publication of CN103153308B publication Critical patent/CN103153308B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN201180049452.3A 2010-10-12 2011-10-11 Trpa1受体拮抗剂 Expired - Fee Related CN103153308B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39213010P 2010-10-12 2010-10-12
US61/392,130 2010-10-12
PCT/SE2011/051213 WO2012050512A1 (en) 2010-10-12 2011-10-11 Trpa1 receptor antagonist

Publications (2)

Publication Number Publication Date
CN103153308A CN103153308A (zh) 2013-06-12
CN103153308B true CN103153308B (zh) 2015-06-03

Family

ID=45938532

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180049452.3A Expired - Fee Related CN103153308B (zh) 2010-10-12 2011-10-11 Trpa1受体拮抗剂

Country Status (5)

Country Link
US (1) US8859556B2 (enExample)
EP (1) EP2627329B1 (enExample)
JP (1) JP5847827B2 (enExample)
CN (1) CN103153308B (enExample)
WO (1) WO2012050512A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014002960A2 (pt) 2011-08-09 2017-02-21 Cubist Pharm Inc inibição de canal de íons potencial receptor transiente trpa1
WO2013108857A1 (ja) 2012-01-17 2013-07-25 味の素株式会社 複素環アミド誘導体及びそれを含有する医薬
US9394308B2 (en) 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
WO2014184248A2 (en) * 2013-05-15 2014-11-20 Acturum Life Science AB Trpa1 antagonist compounds
CN103760286A (zh) * 2014-01-14 2014-04-30 北京万全德众医药生物技术有限公司 一种用高效液相色谱法测定琥珀酸索非那新中间体光学纯度的方法
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
IT202100015098A1 (it) 2021-06-09 2022-12-09 Flonext S R L Composto antagonista del canale trpa1 per uso in patologie degenerative della retina

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1832935A (zh) * 2003-08-01 2006-09-13 欧洲凯尔特公司 用于治疗疼痛的治疗药
WO2008007103A1 (en) * 2006-07-14 2008-01-17 Amura Therapeutics Limited Furo [3, 2-b] pyrrol derivatives
WO2010075353A1 (en) * 2008-12-22 2010-07-01 Hydra Biosciences, Inc. Compositions useful for treating disorders related to trpa1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1770091A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
TW201900217A (zh) 2005-12-22 2019-01-01 美商海卓勒生物科學公司 用於調節ｔｒｐａ１功能之化合物
US9108905B2 (en) 2008-01-04 2015-08-18 Abbvie Inc. TRPA1 antagonists
WO2010004390A1 (en) 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Quinazoline dione derivatives as trpa1 modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1832935A (zh) * 2003-08-01 2006-09-13 欧洲凯尔特公司 用于治疗疼痛的治疗药
WO2008007103A1 (en) * 2006-07-14 2008-01-17 Amura Therapeutics Limited Furo [3, 2-b] pyrrol derivatives
WO2010075353A1 (en) * 2008-12-22 2010-07-01 Hydra Biosciences, Inc. Compositions useful for treating disorders related to trpa1

Also Published As

Publication number Publication date
CN103153308A (zh) 2013-06-12
EP2627329B1 (en) 2015-07-08
WO2012050512A1 (en) 2012-04-19
US8859556B2 (en) 2014-10-14
EP2627329A4 (en) 2014-03-05
JP5847827B2 (ja) 2016-01-27
US20140148466A1 (en) 2014-05-29
EP2627329A1 (en) 2013-08-21
JP2013539781A (ja) 2013-10-28

Similar Documents

Publication Publication Date Title
CN103153308B (zh) Trpa1受体拮抗剂
JP4400566B2 (ja) ベンズアミド誘導体又はその塩
Fuchino et al. Rational design of novel 1, 3-oxazine based β-secretase (BACE1) inhibitors: Incorporation of a double bond to reduce P-gp efflux leading to robust Aβ reduction in the brain
WO2017101803A1 (zh) 一种新型egfr和alk激酶的双重抑制剂
MXPA04010326A (es) Derivados de n-[fenil(piperidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica.
Wu et al. Development of new benzenesulfonamides as potent and selective Nav1. 7 inhibitors for the treatment of pain
JP7746259B2 (ja) 核内受容体に対して活性の化合物
MX2015003637A (es) Piridinonas biciclicas novedosas.
JP6672255B2 (ja) Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法
CA2988421A1 (en) Small molecule analogs of the nemo binding peptide
CA3215075A1 (en) Piperidine urea derivatives as soluble epoxide hydrolase inhibitors
EP3204374B1 (en) Isoindoline derivatives
WO2009147219A1 (en) New compounds vii
CA2845766A1 (en) Benzothiazolone compound
US20090176798A1 (en) New compounds III
CN102159545A (zh) 小分子瘦蛋白受体调节剂
CA2715527A1 (en) New compounds iv
WO2014184248A2 (en) Trpa1 antagonist compounds
EP1683790A1 (en) 3,4-dihydro-2-naphthamide derivatives as selective dopamine D3 ligands
JP2020524708A (ja) Ｒｏｃｋを阻害する化合物及びその使用
CA3195794A1 (en) Dosing regimens for cyclin?dependent kinase 7 (cdk7) inhibitors
CA2882877A1 (en) Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
CN103467391A (zh) 一类含饱和氮杂环酰胺的二芳基甲基哌嗪化合物及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: AKETURAM LIFE SCIENCES AG

Free format text: FORMER OWNER: ASTRAZENECA AB

Effective date: 20141209

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20141209

Address after: Solna, Sweden

Applicant after: ACTURUM LIFE SCIENCE AB

Address before: Swedish Sodertalje

Applicant before: ASTRAZENECA AB

C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20190821

Address after: Solna, Sweden

Patentee after: Akturam Life Co.,Ltd.

Address before: Solna, Sweden

Patentee before: Akturam Real Estate Co.,Ltd.

Effective date of registration: 20190821

Address after: Solna, Sweden

Patentee after: Akturam Real Estate Co.,Ltd.

Address before: Solna, Sweden

Patentee before: ACTURUM LIFE SCIENCE AB

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150603